ISRCTN15180871已完成未知
An open-label safety and pharmacokinetic study of gevokizumab in subjects with Behçet?s disease uveitis
Institut de Recherches Internationales Servier (France)0 个研究点目标入组 21 人开始时间: 2012年4月4日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with uveitis associated with Behçet's disease diagnosis fulfilling the International Study Group Classification Criteria
- •2. Male or female, age [18 or legal age of majority- 80] years old
- •3. Stable regimen of oral corticosteroids and at least one immunosuppressive treatment
排除标准
- •1. Infectious uveitis, uveitis due to causes other than Behçet's disease, or uveitis of unknown origin
- •2. Cataract so severe that an assessment of the posterior segment of the uvea and the fundus is inadequate or impossible
- •3. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
研究者
相似试验
进行中（未招募）
1 期
Pharmacokinetic and Safety Study of Travoprost 0.004% in PediatricGlaucoma PatientsEUCTR2012-001640-22-FRAlcon Research Ltd24
进行中（未招募）
1 期
Pharmacokinetic and Safety Study of Travoprost 0.004% in PediatricGlaucoma PatientsPaediatric glaucomaEUCTR2012-001640-22-GBAlcon Research Ltd25
进行中（未招募）
1 期
Pharmacokinetic and Safety Study of Travoprost 0.004% in PediatricGlaucoma PatientsPaediatric glaucomaEUCTR2012-001640-22-BEAlcon Research Ltd24
进行中（未招募）
不适用
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma PatientsPaediatric glaucomaEUCTR2012-001640-22-ESAlcon Research Ltd24
进行中（未招募）
1 期
Pharmacokinetics of oral hydroxyurea solutioEUCTR2017-004568-37-GBova Laboratories Limited25